价格

TULANE UNIVERSITY HEALTH SCIENCES CENTER

ACTIVE

1430 Tulane Ave, New Orleans, Louisiana, 美国Private

别名:

louisiana center for bleeding and clotting center

tulane cancer center

administrators of the tulane educational fund,the, new orleans, la

tulane doctors

概览

试验阶段分布

阶段

试验数

占比

1 期

23.1%

4 期

23.1%

不适用

15.4%

早期 1 期

7.7%

2 期

7.7%

3 期

7.7%

试验状态分布

已完成

76.9%

撤回

23.1%

药物批准

暂无批准数据

资讯

Expert Panel Debates Treatment Strategies for High-Risk Relapsed CLL Patient with Cardiac Complications

- A 70-year-old CLL patient who relapsed 24 months after venetoclax-obinutuzumab therapy presents with complex karyotype and cardiovascular comorbidities, prompting careful treatment consideration. - Experts discuss the merits of retreating with venetoclax-obinutuzumab versus switching to BTK inhibitors, weighing factors such as prior remission duration and cardiovascular risk. - Recent clinical data shows zanubrutinib demonstrates superior efficacy over ibrutinib in relapsed CLL, while both zanubrutinib and acalabrutinib show improved safety profiles compared to ibrutinib.

Jan 20, 2025

返回机构列表

TULANE UNIVERSITY HEALTH SCIENCES CENTER

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（13）

Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

Trichomonas Vaginalis Repeat Infections Among HIV Negative Women

Using Simulation-Based Training to Incorporate Lung Ultrasound Into Physical Examination

DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women

e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

Study of Macronutrients and Heart Disease Risk

药物批准

资讯

Expert Panel Debates Treatment Strategies for High-Risk Relapsed CLL Patient with Cardiac Complications